Antares Pharma (ATRS) Reports In-Line Q2 EPS

Antares Pharma (NASDAQ: ATRS) reported Q2 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $11 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18